Phased-in approach to implementing EU Falsified Medicines Directive recommended; report
Addressing the fight against counterfeiting, in connection with the Falsified Medicines Directive, the European Generic medicines Association (EGA) has asked professional services firm KPMG to conduct a study on the implementation of technical measures to ensure that this is done in the most stable, cost-effective way for the sake of patient access to medicines and the sustainability of the generic medicines industry in Europe.
The impact assessment (2008) of the European Commission claims that, by 2020, 0.05% of all prescription medicinal products dispensed through the legal supply chain will have been counterfeit products.
The main conclusion set out in KPMG’s independent study is: “With the implementation of safety features, a possible risk of failure and a risk of exceeding the budgeted time and costs can arise.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze